Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 428-432

  Bains, P ^a   Al Tourah, A ^a   Campbell, B A ^b   Pickles, T ^a   Gascoyne, R D ^a   Connors, J M ^a   Savage, K J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Follicular lymphoma; Prognosis; Rituximab; Transformation

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84873881009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds433     Document Type: Article

References (27)

1. Zelenetz AD, Abramson JS, Advani RH et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8(3): 288-334.
2. Dreyling M, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v181-v183.
3. Guadagnolo BA, Li S, Neuberg D et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64(3): 928-934.
4. Lawrence TS, Urba WJ, Steinberg SM et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 1988; 14(3): 417-424.
5. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14(4): 1282-1290.
6. Pendlebury S, el Awadi M, Ashley S. et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 1995; 36(3): 167-171.
7. Campbell BA, Voss N, Woods R et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116(16): 3797-3806.
8. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26 (32): 5165-5169.
9. Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25(17): 2426-2433.
10. Kaplan EL MP. Nonparametric estimation from incomplete observations. Am Stat Assoc 1958; 53: 457-481.
11. Cox DR. Regression models and life tables. J R Stat Assoc 1972; 34: 187-220.
12. Cullen MH, Lister TA, Brearley RI. et al. Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 1979; 44(2): 645-651.
13. Oviatt DL, Cousar JB, Collins RD. et al. Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 1984; 53(5): 1109-1114.
14. Tezcan H, Vose JM, Bast M. et al. Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience. Leuk Lymphoma 1999; 34(3-4): 273-285.
15. Plancarte F, Lopez-Guillermo A, Arenillas L et al. Follicular lymphoma in early stages: high risk of relapse and usefulness of the follicular lymphoma international prognostic index to predict the outcome of patients. Eur J Haematol 2006; 76(1): 58-63.
16. Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15(4): 1587-1594.
17. Gentles AJ, Alizadeh AA, Lee SI et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood 2009; 114(15): 3158-3166.
18. Farinha P, Al-Tourah A, Gill K. et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115(2): 289-295.
19. Farinha P, Kyle AH, Minchinton AI. et al. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010; 95(12): 2157-2160.
20. Lepage E, Sebban C, Gisselbrecht C et al. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematol Oncol 1990; 8(1): 31-39.
21. Al-Tourah A, Gill K, Hoskins P et al. The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006; 24(18S): 7510.
22. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-242.
23. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116(12): 2040-2045.
24. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9(2): 105-116.
25. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-391.
26. Al-Tourah A, Savage K, Gill K. et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annual Meeting Abstracts. 2007; 110(11): (Abstr. 790).
27. Tan D, Rosenberg S, Lavori P. et al. Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): the stanford experience 1960- 2003. Ann Oncol 2008; 19(Suppl 4): (Abstr 89).